Cargando…

Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma

Lymphoma cells expressing CD5 (CD5+) confer inferior outcome of diffuse large B-cell lymphoma (DLBCL), especially in non–MYC/BCL2 double expressor (non-DE) patients. In tumor microenvironment, CD5+ non-DE tumor revealed increased proportion of immunosuppressive M2 macrophages and enhanced pathways r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Meng-Ke, Cheng, Li-Li, Yi, Hong-Mei, He, Yang, Li, Xiao, Fu, Di, Dai, Yu-Ting, Fang, Hai, Cheng, Shu, Xu, Peng-Peng, Qian, Ying, Feng, Yan, Liu, Qian, Wang, Li, Zhao, Wei-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583025/ https://www.ncbi.nlm.nih.gov/pubmed/36276140 http://dx.doi.org/10.3389/fonc.2022.885011

Ejemplares similares

Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma
por: Zhong, Xing, et al.
Publicado: (2021)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation
por: Hashmi, Atif A, et al.
Publicado: (2021)

Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors
por: Na, Hee Young, et al.
Publicado: (2019)

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
por: Melchor, Javier, et al.
Publicado: (2023)

A Great Mimicker in Thoracic Spine: Spinal Double Expressor Lymphoma
por: Mufti, Muhammad, et al.
Publicado: (2018)

Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma
por: Takada, Ryutaro, et al.
Publicado: (2021)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Double-Expressor Appendiceal Burkitt's Lymphoma: A Case Report and Literature Review
por: Dukmak, Osama N., et al.
Publicado: (2022)

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023)

Multiple osteolytic lesions due to Double-Expressor Primary non-Hodgkin Lymphoma of the Bone
por: Papageorgiou, Sotirios, et al.
Publicado: (2020)

Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma
por: Peña, Camila, et al.
Publicado: (2020)

Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
por: Craig, Jeffrey W., et al.
Publicado: (2018)

PB2122: THE EFFICACY OF THE STANDARD AND INTENSIVE CHEMOTHERAPY IN ELDERLY PATIENTS WITH DOUBLE- AND TRIPLE-EXPRESSOR LYMPHOMA.
por: Fujita, M., et al.
Publicado: (2022)

Prognostic evaluation of system immune-inflammatory index and prognostic nutritional index in double expressor diffuse large B-cell lymphoma
por: Su, Fang, et al.
Publicado: (2023)

Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report
por: Xie, Fan, et al.
Publicado: (2021)

Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL
por: Rungwittayatiwat, Sirapat, et al.
Publicado: (2021)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant
por: Parkhi, Mayur, et al.
Publicado: (2023)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

Triple Expressor Lymphoma: Presentation With Acute Paraparesis Due to Spinal Cord Compression
por: Alburqueque-Melgarejo, Joseph, et al.
Publicado: (2022)

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2014)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of in vitro high-throughput drug sensitivity test
por: Xing, Lijie, et al.
Publicado: (2023)

Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Upper Limb: Double Hit/Double Expressor with CNS Involvement: From Hospice to Remission
por: Castillo, Brenda S., et al.
Publicado: (2019)

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2018)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis
por: Zhan, Jing, et al.
Publicado: (2022)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

Double‑hit primary lymphoma (MYC and BCL2) in the bilateral ovary: A case report
por: Zhang, Yan, et al.
Publicado: (2023)

Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma
por: Li, Shaoying, et al.
Publicado: (2016)

Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology
por: Zhou, Jianbo, et al.
Publicado: (2022)

“Double hit” B-lymphoblastic lymphoma with concurrent IGH/BCL2 and 8q24/MYC translocations: a case report
por: He, Lu, et al.
Publicado: (2021)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hobtpvp12k3er6oqaoqkoi68uf